𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

✍ Scribed by Cleary, James M.; Lima, Caio Max S. Rocha; Hurwitz, Herbert I.; Montero, Alberto J.; Franklin, Catherine; Yang, Jianning; Graham, Alison; Busman, Todd; Mabry, Mack; Holen, Kyle; Shapiro, Geoffrey I.; Uronis, Hope

Book ID
125358951
Publisher
Springer US
Year
2014
Tongue
English
Weight
408 KB
Volume
32
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I clinical trial of bortezomib in
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 114 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi

Phase I Study of Navitoclax (ABT-263), a
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
✍ Gandhi, L.; Camidge, D. R.; Ribeiro de Oliveira, M.; Bonomi, P.; Gandara, D.; Kh πŸ“‚ Article πŸ“… 2011 πŸ› American Society of Clinical Oncology 🌐 English βš– 299 KB

## Purpose Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conduct